Inflammation and cancer: tissue regeneration gone awry

Current Opinion in Cell Biology

Volumn 43, Issue , 2016, Pages 55-61

  Pesic, Marina ^a   Greten, Florian R ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE; CYTOKINE; MICRORNA 34A; TUMOR SUPPRESSOR PROTEIN;

CHRONIC INFLAMMATION; COLON CARCINOGENESIS; DISEASE MARKER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TISSUE REGENERATION; TUMOR GROWTH; ANIMAL; CARCINOGENESIS; HUMAN; INFLAMMATION; NEOPLASMS; PATHOLOGY; REGENERATION; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOGENESIS; HUMANS; INFLAMMATION; NEOPLASMS; REGENERATION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84989867588     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2016.07.010     Document Type: Review

References (49)

1. 1 Kundu, J.K., Surh, Y.J., Inflammation: gearing the journey to cancer. Mutat Res 659 (2008), 15–30.
2. 2 Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
3. 3 Shalapour, S., Karin, M., Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125 (2015), 3347–3355.
4. 4 Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
5. 5 Karin, M., Clevers, H., Reparative inflammation takes charge of tissue regeneration. Nature 529 (2016), 307–315.
6. 6 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
7. 7 Crusz, S.M., Balkwill, F.R., Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12 (2015), 584–596.
8. 8 Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444.
9. 9 Rose-John, S., Mitsuyama, K., Matsumoto, S., Thaiss, W.M., Scheller, J., Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des 15 (2009), 2095–2103.
10. 10 Putoczki, T.L., Thiem, S., Loving, A., Busuttil, R.A., Wilson, N.J., Ziegler, P.K., Nguyen, P.M., Preaudet, A., Farid, R., Edwards, K.M., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24 (2013), 257–271.
11. 11 Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15 (2009), 103–113.
12. 12 Tanaka, T., Narazaki, M., Kishimoto, T., Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52 (2012), 199–219.
13. 13 Garbers, C., Hermanns, H.M., Schaper, F., Muller-Newen, G., Grotzinger, J., Rose-John, S., Scheller, J., Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23 (2012), 85–97.
14. 14 Kishimoto, T., IL-6: from its discovery to clinical applications. Int Immunol 22 (2010), 347–352.
15. 15•• Taniguchi, K., Wu, L.W., Grivennikov, S.I., de Jong, P.R., Lian, I., Yu, F.X., Wang, K., Ho, S.B., Boland, B.S., Chang, J.T., et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519 (2015), 57–62 IL-6 activates Notch through gp130-Src-YAP independently of STAT3.
16. 16 Piccolo, S., Dupont, S., Cordenonsi, M., The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94 (2014), 1287–1312.
17. 17 Azzolin, L., Panciera, T., Soligo, S., Enzo, E., Bicciato, S., Dupont, S., Bresolin, S., Frasson, C., Basso, G., Guzzardo, V., et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158 (2014), 157–170.
18. 18•• Rokavec, M., Oner, M.G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P.K., Schwitalla, S., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 124 (2014), 1853–1867 P53 is a novel regulator of IL-6 through its transcriptional target miR-34a.
19. 19 Hussain, S.P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W.P., Shields, P.G., Ham, A.J., Swenberg, J.A., Marrogi, A.J., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60 (2000), 3333–3337.
20. 20 Schwitalla, S., Ziegler, P.K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann, Y., Lechel, A., Rudolph, K.L., Langer, R., Slotta-Huspenina, J., et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23 (2013), 93–106.
21. 21 Cooks, T., Pateras, I.S., Tarcic, O., Solomon, H., Schetter, A.J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rosenfeld, N., et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23 (2013), 634–646.
22. 22 Spehlmann, M.E., Manthey, C.F., Dann, S.M., Hanson, E., Sandhu, S.S., Liu, L.Y., Abdelmalak, F.K., Diamanti, M.A., Retzlaff, K., Scheller, J., et al. Trp53 deficiency protects against acute intestinal inflammation. J Immunol 191 (2013), 837–847.
23. 23 He, X.Y., Xiang, C., Zhang, C.X., Xie, Y.Y., Chen, L., Zhang, G.X., Lu, Y., Liu, G., p53 in the myeloid lineage modulates an inflammatory microenvironment limiting initiation and invasion of intestinal tumors. Cell Rep 13 (2015), 888–897.
24. 24• Bu, P., Wang, L., Chen, K.Y., Srinivasan, T., Murthy, P.K., Tung, K.L., Varanko, A.K., Chen, H.J., Ai, Y., King, S., et al. A miR-34a-Numb feedforward loop triggered by inflammation regulates asymmetric stem cell division in intestine and colon cancer. Cell Stem Cell 18 (2016), 189–202 MiR-34a acts protectively in inflammation limiting number of intestinal stem cells via enforcement of asymmetric division.
25. 25 Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P.J., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449 (2007), 1003–1007.
26. 26 Snippert, H.J., van der Flier, L.G., Sato, T., van Es, J.H., van den Born, M., Kroon-Veenboer, C., Barker, N., Klein, A.M., van Rheenen, J., Simons, B.D., et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143 (2010), 134–144.
27. 27• Bu, P., Chen, K.Y., Chen, J.H., Wang, L., Walters, J., Shin, Y.J., Goerger, J.P., Sun, J., Witherspoon, M., Rakhilin, N., et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 12 (2013), 602–615 MiR-34a controls a choice of daughter cells to self-renew or differentiate during division through direct targeting of Notch.
28. 28•• Westphalen, C.B., Asfaha, S., Hayakawa, Y., Takemoto, Y., Lukin, D.J., Nuber, A.H., Brandtner, A., Setlik, W., Remotti, H., Muley, A., et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. J Clin Invest 124 (2014), 1283–1295 Dclk1+ tuft cells maintain quiescence even following Apc mutation but serve to initiate cancer after inflammatory damage.
29. 29 Nakanishi, Y., Seno, H., Fukuoka, A., Ueo, T., Yamaga, Y., Maruno, T., Nakanishi, N., Kanda, K., Komekado, H., Kawada, M., et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 45 (2013), 98–103.
30. 30 Westphalen, C.B., Takemoto, Y., Tanaka, T., Macchini, M., Jiang, Z., Renz, B.W., Chen, X., Ormanns, S., Nagar, K., Tailor, Y., et al. Dclk1 defines quiescent pancreatic progenitors that promote injury-induced regeneration and tumorigenesis. Cell Stem Cell 18 (2016), 441–455.
31. 31 Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M.A., Caldwell, M.E., Allard, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
32. 32 Theunissen, J.W., de Sauvage, F.J., Paracrine Hedgehog signaling in cancer. Cancer Res 69 (2009), 6007–6010.
33. 33 Feig, C., Gopinathan, A., Neesse, A., Chan, D.S., Cook, N., Tuveson, D.A., The pancreas cancer microenvironment. Clin Cancer Res 18 (2012), 4266–4276.
34. 34 Amakye, D., Jagani, Z., Dorsch, M., Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 19 (2013), 1410–1422.
35. 35•• Rhim, A.D., Oberstein, P.E., Thomas, D.H., Mirek, E.T., Palermo, C.F., Sastra, S.A., Dekleva, E.N., Saunders, T., Becerra, C.P., Tattersall, I.W., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 (2014), 735–747 Deletion of Shh or pharmacological inhibition of Smoothened reduces stromal desmoplasia but tumor growth was accelerated, metastasis and vascularization increased. Combined treatment with VEGF inhibitor prolongs survival.
36. 36•• Ozdemir, B.C., Pentcheva-Hoang, T., Carstens, J.L., Zheng, X., Wu, C.C., Simpson, T.R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S.V., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 (2014), 719–734 Myofibroblasts depletion increases tumor invasion, stem cell like phenotype and regulatory T cell infiltration and Ctla4 expression. Myofibroblasts depletion allows successful immune checkpoint targeting and prolongs survival.
37. 37•• Pallangyo, C.K., Ziegler, P.K., Greten, F.R., IKKbeta acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J Exp Med 212 (2015), 2253–2266 Conditional fibroblasts specific IKKbeta deletion increases HGF secretion, intestinal epithelial cell proliferation, angiogenesis, stem cell properties and regulatory T cell recruitment.
38. 38•• Koliaraki, V., Pasparakis, M., Kollias, G., IKKbeta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med 212 (2015), 2235–2251 Constitutive fibroblast specific IKKbeta deletion decreases IL-6, intestinal epithelial cell proliferation and EMT.
39. 39 Wagner, E.F., Cancer: fibroblasts for all seasons. Nature 530 (2016), 42–43.
40. 40 Masferrer, J.L., Leahy, K.M., Koki, A.T., Zweifel, B.S., Settle, S.L., Woerner, B.M., Edwards, D.A., Flickinger, A.G., Moore, R.J., Seibert, K., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000), 1306–1311.
41. 41 Algra, A.M., Rothwell, P.M., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13 (2012), 518–527.
42. 42 Rothwell, P.M., Price, J.F., Fowkes, F.G., Zanchetti, A., Roncaglioni, M.C., Tognoni, G., Lee, R., Belch, J.F., Wilson, M., Mehta, Z., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379 (2012), 1602–1612.
43. 43 Rothwell, P.M., Wilson, M., Price, J.F., Belch, J.F., Meade, T.W., Mehta, Z., Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379 (2012), 1591–1601.
44. 44 Cuzick, J., Thorat, M.A., Bosetti, C., Brown, P.H., Burn, J., Cook, N.R., Ford, L.G., Jacobs, E.J., Jankowski, J.A., La Vecchia, C., et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26 (2015), 47–57.
45. 45 Li, X.J., Ren, Z.J., Tang, J.H., MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis, 5, 2014, e1327.
46. 46 Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
47. 47 Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
48. 48 Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
49. 49 Gupta, K., Tiu, D.Y., Tiu, J., Aragon-Ching, J.B., The promising role of nivolumab in renal cell cancers. Cancer Biol Ther 17 (2016), 123–124.